Table 2.
Description of intervention components included in Cochrane reviews of probiotics and GI conditions.
| Author, Year | Exclusive number of probiotics per review N |
Trials that specify strain N (%) |
Trials that indicate dosage N (%) |
Trials that specify intervention length N (%) |
Trials that specify follow-up N (%) |
|---|---|---|---|---|---|
| Goldenberg et al. (2015) [35] | 17 | 11 (48%) | 23 (100%) | 7* (30%) | 17 (74%) |
| Bernaola Aponte et al. (2013) [34] | 4 | 3 (75%) | 4 (100%) | 4 (100%) | 0 (0%) |
| Allen et al. (2010) [33] | 21 | 42 (67%) | 62 (98%) | 45 (71%) | 0 (0%) |
| Goldenberg et al. (2013) [36] | 14 | 21 (68%) | 30 (97%) | 31 (100%) | 24 (77%) |
| Pillai et al. (2010) [37] | 3 | 4 (100%) | 4 (100%) | 4 (100%) | 4 (100%) |
| Rolfe et al. (2006) [40] | 4 | 6 (86%) | 7 (100%) | 7 (100%) | 0 (0%) |
| Butterworth et al. (2008) [38] | 1 | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) |
| Doherty et al. (2010) [39] | 4 | 3 (60%) | 1 (20%) | 5 (100%) | 0 (0%) |
| Naidoo et al. (2011) [43] | 3 | 4 (100%) | 4 (100%) | 4 (100%) | 0 (0%) |
| Mallon et al. (2010) [42] | 4 | 1 (25%) | 4 (100%) | 4 (100%) | 0 (0%) |
| Chande et al. (2009) [41] | 1 | 1 (100%) | 1 (100%) | 1 (100%) | 1 (100%) |
| Singh et al. (2015) [44] | 3 | 2 (33%) | 5 (83%) | 6 (100%) | 0 (0%) |
| Lirussi et al. (2009) [45] | n/a | n/a | n/a | (n/a) | n/a |
| McGee et al. (2011) [46] | 7 | 1 (14%) | 5 (71%) | 7 (100%) | 0 (0%) |
*
Review paper lists the range of intervention length within the results text but it is not listed specifically for each study.